- Home
- SEMR vs JANX Comparison
SEMR vs JANX Comparison
Compare SEMR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- JANX
- Stock Information
- Founded
- SEMR 2008
- JANX 2017
- Country
- SEMR United States
- JANX United States
- Employees
- SEMR N/A
- JANX N/A
- Industry
- SEMR EDP Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- JANX Health Care
- Exchange
- SEMR Nasdaq
- JANX Nasdaq
- Market Cap
- SEMR 1.4B
- JANX 1.4B
- IPO Year
- SEMR 2021
- JANX 2021
- Fundamental
- Price
- SEMR $9.11
- JANX $23.22
- Analyst Decision
- SEMR Buy
- JANX Strong Buy
- Analyst Count
- SEMR 8
- JANX 7
- Target Price
- SEMR $17.00
- JANX $94.29
- AVG Volume (30 Days)
- SEMR 978.5K
- JANX 665.3K
- Earning Date
- SEMR 08-04-2025
- JANX 08-06-2025
- Dividend Yield
- SEMR N/A
- JANX N/A
- EPS Growth
- SEMR N/A
- JANX N/A
- EPS
- SEMR 0.05
- JANX N/A
- Revenue
- SEMR $396,021,000.00
- JANX $9,336,000.00
- Revenue This Year
- SEMR $21.84
- JANX N/A
- Revenue Next Year
- SEMR $18.46
- JANX $1,470.82
- P/E Ratio
- SEMR $190.99
- JANX N/A
- Revenue Growth
- SEMR 22.75
- JANX 28.12
- 52 Week Low
- SEMR $7.90
- JANX $22.48
- 52 Week High
- SEMR $18.74
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- SEMR 40.28
- JANX 41.76
- Support Level
- SEMR $8.70
- JANX $22.56
- Resistance Level
- SEMR $9.17
- JANX $24.19
- Average True Range (ATR)
- SEMR 0.30
- JANX 1.28
- MACD
- SEMR -0.01
- JANX 0.02
- Stochastic Oscillator
- SEMR 17.05
- JANX 15.32
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.